← Leaderboards
Arash Hatefi
Rutgers, The State Univ Of N.J.
$4,338,134
Attributed
$4,338,134
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $625.5K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,338,134 · 4
By mechanism
R01$3,676,384 · 2
R21$661,750 · 2
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Toxic Effect”
- George R Seage · Abt Associates, Inc.$224,114,540
- Peter C Adamson · National Childhood Cancer Foundation$126,756,857
- Gregory H Reaman · National Childhood Cancer Foundation$123,836,183
- Carol Nesel · Westat$116,355,411
- Mary M Horowitz · Medical College Of Wisconsin$90,165,506
- Barney Sparrow · Battelle Memorial Institute$88,494,220
Research focus
Toxic EffectCellsTumor XenograftEnzymesCancer CellTumorProdrugsMalignant NeoplasmsPharmaceutical PreparationsTissuesResponseCisplatinOperative Surgical ProceduresNormal Tissue MorphologyMalignant Neoplasm Of OvaryChemotherapyClinicEffectivenessAntineoplastic AgentsCancer PatientBiodistributionEnzyme ActivityCancer RelapseDrug Delivery Systems
Grant awards (13)
Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer$389,984
R01 · FY2025 · CA · contact PI
Trispecific Killer Cell Engager for the Treatment of Systemic Lupus Erythematosus$235,500
R21 · FY2025 · AI · contact PI
Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer$370,485
R01 · FY2024 · CA · contact PI
Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer$382,186
R01 · FY2023 · CA · contact PI
Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer$382,186
R01 · FY2022 · CA · contact PI
Stem Cell-based Platform for Targeted Enzyme/Prodrug Therapy of Recurrent Ovarian Cancer$389,366
R01 · FY2021 · CA · contact PI
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer$343,925
R01 · FY2019 · CA · contact PI
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer$354,563
R01 · FY2018 · CA · contact PI
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer$354,563
R01 · FY2017 · CA · contact PI
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer$354,563
R01 · FY2016 · CA · contact PI
A Nanotechnology Platform for Suicide Gene Therapy of Recurring Ovarian Cancer$354,563
R01 · FY2015 · CA · contact PI
Bioengineering a Safe and Efficient Vector Technology for Stem Cell Transfection$193,750
R21 · FY2015 · EB · contact PI
Bioengineering a Safe and Efficient Vector Technology for Stem Cell Transfection$232,500
R21 · FY2014 · EB · contact PI